TP53 and rhabdomyosarcoma: In summary, in addition to its known tumor-suppressing activity, in specific contexts, and in particular in the absence of p53, p19Arf was found to favor carcinogenesis, exactly as it appears to do in our rhabdomyosarcoma model.